Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Receivables - Net (2016 - 2025)

Historic Receivables - Net for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $54.6 million.

  • Vanda Pharmaceuticals' Receivables - Net rose 1587.44% to $54.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $54.6 million, marking a year-over-year increase of 1587.44%. This contributed to the annual value of $54.6 million for FY2025, which is 1587.44% up from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Receivables - Net of $54.6 million as of Q4 2025, which was up 1587.44% from $50.5 million recorded in Q3 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Receivables - Net ranged from a high of $54.6 million in Q4 2025 and a low of $24.5 million during Q1 2023
  • Its 5-year average for Receivables - Net is $37.5 million, with a median of $35.4 million in 2023.
  • In the last 5 years, Vanda Pharmaceuticals' Receivables - Net soared by 5085.21% in 2021 and then crashed by 2926.55% in 2022.
  • Vanda Pharmaceuticals' Receivables - Net (Quarter) stood at $32.5 million in 2021, then rose by 3.22% to $33.5 million in 2022, then grew by 1.92% to $34.2 million in 2023, then soared by 37.9% to $47.1 million in 2024, then increased by 15.87% to $54.6 million in 2025.
  • Its Receivables - Net stands at $54.6 million for Q4 2025, versus $50.5 million for Q3 2025 and $45.0 million for Q2 2025.